OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business

Buy One Founder Summit Ticket, Get a Second for Free. Register now.

Disrupt doors open Oct. 13. Get your pass and bring someone with you at 50% off. REGISTER NOW.

OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced via its website. Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC.

Orchestra creates AI agents that help biotech companies manage the minutiae of drug discovery operations, from tracking finances to resolving scheduling issues with clinical trials.

OpenAI says it’s adding Orchestra’s team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results. OpenAI has already won some big names as customers for Rosalind, including, it says, Moderna⁠ and Novo Nordisk⁠.

The acquisition is a classic example of how the biggest AI labs (namely OpenAI and Anthropic) are building ever more software for the biggest industries, like pharma. In the startup world, there is an ongoing fear that at any moment, the labs will launch new features and become competitors. In this case, Orchestra is getting absorbed, rather than stomped out.

Buy One Pass, Get a Second FreeCover more ground at TechCrunch’s ultimate founder bootcamp of the year by bringing your co-founder or partner for freeBook before the BOGO deal expires

Every weekday and Sunday, you can get the best of TechCrunch’s coverage.

TechCrunch Mobility is your destination for transportation news and insight.

Startups are the core of TechCrunch, so get our best coverage delivered weekly.

Provides movers and shakers with the info they need to start their day.

By submitting your email, you agree to our Terms and Privacy Notice.